.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,816,379

« Back to Dashboard
Patent 7,816,379 protects SIVEXTRO and is included in two NDAs.

This patent has twenty-nine patent family members in nineteen countries.

Summary for Patent: 7,816,379

Title:Oxazolidinone derivatives
Abstract: The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.
Inventor(s): Rhee; Jae Keol (Suwan, KR), Im; Weon Bin (Yongin-si, KR), Cho; Chong Hwan (Yongin-si, KR), Choi; Sung Hak (Seongnam-si, KR), Lee; Tae Ho (Yongin-si, KR)
Assignee: Dong-A Pharm. Co., Ltd. (Seoul, KR)
Application Number:10/596,412
Patent Claim Types:
see list of patent claims
Process; Use; Compound; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 36th percentile
Forward Citations: 4th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cubist Pharms Llc
SIVEXTRO
tedizolid phosphate
TABLET;ORAL205435-001Jun 20, 2014RXYes7,816,379► subscribeYY METHOD OF TREATING BACTERIAL INFECTIONS
Cubist Pharms Llc
SIVEXTRO
tedizolid phosphate
POWDER;IV (INFUSION)205436-001Jun 20, 2014RXYes7,816,379► subscribeYY METHOD OF TREATING BACTERIAL INFECTIONS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,816,379

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2003-0093342Dec 18, 2003
South Korea10-2004-0058809Jul 27, 2004
PCT Information
PCT FiledDecember 17, 2004PCT Application Number:PCT/KR2004/003327
PCT Publication Date:June 30, 2005PCT Publication Number: WO2005/058886

Non-Orange Book Patents for Patent: 7,816,379

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,420,676Oxazolidinone derivatives► subscribe
9,163,043Oxazolidinone derivatives► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,816,379

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1699784► subscribe92834Luxembourg► subscribe
European Patent Office1699784► subscribeC300759Netherlands► subscribe
European Patent Office1699784► subscribeCA 2015 00048Denmark► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc